Vergelijking

KPV vs. TB-500

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Genezing

CAS-nr.

67727-97-3

geen gegevens

Molecuulmassa

342.4 g/mol

888 g/mol

Halfwaardetijd

geen gegevens

Sequentie

KPV

Ac-LKKTETQ

Werkingsmechanisme

KPV

KPV is the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH). In preclinical models the inflammation-modulating activity is attributed predominantly to inhibition of the NF-κB and MAP-kinase signalling pathways, accompanied by reduced release of pro-inflammatory mediators. Cellular uptake via the peptide transporter PepT1 has also been described. The precise molecular mechanisms are not conclusively understood and not confirmed in humans.

TB-500

Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.

Bewijsbasis

Hoogste bewijs

Diermodel

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	KPV	TB-500
Australië	—	Verboden
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Alleen onderzoek	Alleen onderzoek

Volledige vermeldingen

KPV

Volledige vermelding →

TB-500

Volledige vermelding →

Frequently asked questions

What is the difference between KPV and TB-500?: KPV is classified as "Genezing", while TB-500 is classified as "Genezing". KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, KPV or TB-500?: The highest available evidence level is "Diermodel" for KPV and "Diermodel" for TB-500. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of KPV and TB-500 in Germany and the United States?: Duitsland: KPV — Niet goedgekeurd, TB-500 — Niet goedgekeurd. Verenigde Staten: KPV — Alleen onderzoek, TB-500 — Alleen onderzoek. These are factual summaries with source and review date on the individual pages.

Country

KPV

TB-500

Australië

—

Verboden

Duitsland

Niet goedgekeurd

Verenigde Staten

Alleen onderzoek

Frequently asked questions

What is the difference between KPV and TB-500?

KPV is classified as "Genezing", while TB-500 is classified as "Genezing". KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. TB-500: Synthetic fragment of the endogenous protein Thymosin Beta-4, specifically the actin-binding sequence. Preclinical models investigate effects on cell migration, neovascularisation and wound healing — robust human data are absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, KPV or TB-500?

The highest available evidence level is "Diermodel" for KPV and "Diermodel" for TB-500. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of KPV and TB-500 in Germany and the United States?

Duitsland: KPV — Niet goedgekeurd, TB-500 — Niet goedgekeurd. Verenigde Staten: KPV — Alleen onderzoek, TB-500 — Alleen onderzoek. These are factual summaries with source and review date on the individual pages.